NeoGenomics, Inc. (NASDAQ:NEO) Given Average Recommendation of “Hold” by Brokerages

NeoGenomics, Inc. (NASDAQ:NEO) has been given a consensus rating of “Hold” by the fifteen analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $12.00.

A number of analysts have recently commented on the company. Cowen reissued a “buy” rating on shares of NeoGenomics in a research note on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of NeoGenomics in a research report on Monday, December 29th. Finally, Leerink Partners set a $14.00 target price on shares of NeoGenomics in a report on Tuesday, October 28th.

NeoGenomics Stock Performance

Shares of NeoGenomics stock opened at $13.16 on Friday. The company’s 50 day moving average price is $11.57 and its two-hundred day moving average price is $9.06. The firm has a market capitalization of $1.70 billion, a P/E ratio of -14.95 and a beta of 1.58. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.91 and a quick ratio of 3.62. NeoGenomics has a fifty-two week low of $4.72 and a fifty-two week high of $17.75.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings results on Tuesday, October 28th. The medical research company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.01. The company had revenue of $187.80 million during the quarter, compared to analysts’ expectations of $183.85 million. NeoGenomics had a negative return on equity of 3.36% and a negative net margin of 16.00%.NeoGenomics’s revenue was up 12.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.05 EPS. NeoGenomics has set its FY 2025 guidance at 0.080-0.120 EPS. On average, equities analysts forecast that NeoGenomics will post -0.2 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other NeoGenomics news, EVP Alicia C. Olivo sold 20,916 shares of the stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $12.00, for a total transaction of $250,992.00. Following the completion of the sale, the executive vice president owned 31,083 shares of the company’s stock, valued at approximately $372,996. This represents a 40.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.40% of the stock is owned by insiders.

Institutional Investors Weigh In On NeoGenomics

Hedge funds have recently added to or reduced their stakes in the company. First Light Asset Management LLC increased its holdings in shares of NeoGenomics by 45.0% during the third quarter. First Light Asset Management LLC now owns 9,927,269 shares of the medical research company’s stock valued at $76,639,000 after acquiring an additional 3,080,837 shares in the last quarter. Greenhouse Funds LLLP grew its position in NeoGenomics by 10.6% in the 3rd quarter. Greenhouse Funds LLLP now owns 8,220,657 shares of the medical research company’s stock valued at $63,463,000 after purchasing an additional 789,510 shares during the period. American Century Companies Inc. increased its stake in NeoGenomics by 6.0% during the 2nd quarter. American Century Companies Inc. now owns 3,517,478 shares of the medical research company’s stock valued at $25,713,000 after purchasing an additional 197,876 shares in the last quarter. Geode Capital Management LLC raised its holdings in NeoGenomics by 0.8% during the second quarter. Geode Capital Management LLC now owns 3,156,621 shares of the medical research company’s stock worth $23,078,000 after buying an additional 26,224 shares during the last quarter. Finally, Segall Bryant & Hamill LLC lifted its stake in shares of NeoGenomics by 0.5% in the second quarter. Segall Bryant & Hamill LLC now owns 2,362,049 shares of the medical research company’s stock valued at $17,267,000 after buying an additional 11,303 shares in the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.

About NeoGenomics

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.